Research Article

Upregulated GSDMB in Clear Cell Renal Cell Carcinoma Is Associated with Immune Infiltrates and Poor Prognosis

Table 1

The clinical characteristics of ccRCC patients between the high GSDMB expression group and low expression group.

CharacteristicLow expression of GSDMBHigh expression of GSDMB

269270
T stage, (%)0.040
 T1154 (28.6%)124 (23%)
 T233 (6.1%)38 (7.1%)
 T379 (14.7%)100 (18.6%)
 T43 (0.6%)8 (1.5%)
N stage, (%)0.593
 N0115 (44.7%)126 (49%)
 N16 (2.3%)10 (3.9%)
M stage, (%)0.358
 M0225 (44.5%)203 (40.1%)
 M136 (7.1%)42 (8.3%)
Pathologic stage, (%)0.093
 Stage I150 (28%)122 (22.8%)
 Stage II28 (5.2%)31 (5.8%)
 Stage III52 (9.7%)71 (13.2%)
 Stage IV38 (7.1%)44 (8.2%)
Primary therapy outcome, (%)0.861
 PD5 (3.4%)6 (4.1%)
 SD4 (2.7%)2 (1.4%)
 PR1 (0.7%)1 (0.7%)
 CR76 (51.7%)52 (35.4%)
Gender, (%)0.433
 Female88 (16.3%)98 (18.2%)
 Male181 (33.6%)172 (31.9%)
Race, (%)0.057
 Asian1 (0.2%)7 (1.3%)
 Black or African American25 (4.7%)32 (6%)
 White239 (44.9%)228 (42.9%)
Age, (%)0.064
 ≤60123 (22.8%)146 (27.1%)
 >60146 (27.1%)124 (23%)
Histologic grade, (%)0.324
 G16 (1.1%)8 (1.5%)
 G2126 (23.7%)109 (20.5%)
 G399 (18.6%)108 (20.3%)
 G432 (6%)43 (8.1%)
Serum calcium, (%)0.446
 Elevated3 (0.8%)7 (1.9%)
 Low104 (28.4%)99 (27%)
 Normal75 (20.5%)78 (21.3%)
Hemoglobin, (%)0.073
 Elevated2 (0.4%)3 (0.7%)
 Low125 (27.2%)138 (30.1%)
 Normal111 (24.2%)80 (17.4%)
Laterality, (%)0.012
 Left111 (20.6%)141 (26.2%)
 Right158 (29.4%)128 (23.8%)
OS event, (%)<0.001
 Alive203 (37.7%)163 (30.2%)
 Dead66 (12.2%)107 (19.9%)
DSS event, (%)0.006
 Alive224 (42.4%)196 (37.1%)
 Dead41 (7.8%)67 (12.7%)
PFI event, (%)0.140
 Alive197 (36.5%)181 (33.6%)
 Dead72 (13.4%)89 (16.5%)
Age, median (IQR)61 (53, 70)60 (51, 69)0.351

ccRCC: clear cell renal cell carcinoma.